Skip to main content
. 2018 Jul 18;8:10898. doi: 10.1038/s41598-018-29170-7

Table 4.

Change between baseline and year 1 evaluation in muscle function tests, spirometry, quantitative muscle MRI and patient reported outcome measures in symptomatic and asymptomatic LOPD patients.

Symptomatic treated patients (baseline vs. 12-month follow-up) (n = 22) P value Asymptomatic patients (baseline vs. 12-month follow-up) (n = 10) P value
Muscle function tests
MRC total, score 0 (−4; +6) 0.79 0 (0; +1) 0.31
MRC Lower limbs, score 0 (−5; +4) 0.54 0 (0) 0.31
Knee extension (Nm) 10.74 (0; +20.44) 0.19 −0.96 (−18.11; +3.15) 0.40
Knee flexion (Nm) 1.84 (−1.26; +5.97) 0.20 −0.51 (−10.13; +6.43) 0.67
Hip flexion (Nm) 3.97 (−1.7; +9.84) 0.14 −0.75 (−15.1; +3.9) 0.40
Hip extension (Nm) 2 (−0.13; +5.47) 0.08 −4.15 (−16.04; +1.82) 0.40
6-MWT, m 0 (−9.5; +11) 0.96 10 (−24.7; +7.5) 0.48
Time to walk 10 m, seconds 0(−1.44; +0.4) 0.43 −0.1(−2.52; +0.32) 0.91
Time to climb 4 steps, seconds 0 (−0.42; +0.5) 0.77 −0.1 (−0.32; 0) 0.39
Time to descend 4 steps, seconds 0 (−0.35; +1.32) 0.43 −0.05 (−0.12; +0.1) 0.55
Timed up & go test, sec 0.6 (−0.4; +5.2) 0.47 −0.15 (−0.72; +0.97) 0.94
MFM-20, score 0 (−2; +2) 0.63 0 (0; +1) 0.33
Respiratory studies
CVF seated (%) −0.3 (−4; +3) 0.24 0 (−6; +5.77) 0.73
CVF lying (%) 0 (−6.2; +7.62) 0.73 9 (−2; +12) 0.13
Muscle MRI
qMRI Thighs 1.79 (+0.2; +2.4) 0.001 −0.11 (−0.82; +0.4) 0.57
qMRI Paraspinal −0.03 (−2.23; +0.73) 0.34 0 (−1.25; +1.89) 0.77
Patient-reported outcomes
Activlim 33 (+1; +59) 0.81 67.5 (+37.5; +70.2) 0.31
SF36 1.8 (+0.67; +10.73) 0.22 3.28 (+24.84; +10.12) 0.89
INQoL −2.9 (−5.5; +0.73) 0.17 −4.3 (−8.2; +1.1) 0.31

Median value and 25th–75th percentiles are shown. Paired Wilcoxon signed rank test was used to find out whether the differences observed between baseline and year 1 evaluation were statistically significant. Adjustment for multiple comparisons using Bonferroni correction was applied; p was considered significant if lower than 0.002.